[go: up one dir, main page]

PL2380587T3 - Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu - Google Patents

Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu

Info

Publication number
PL2380587T3
PL2380587T3 PL11172880T PL11172880T PL2380587T3 PL 2380587 T3 PL2380587 T3 PL 2380587T3 PL 11172880 T PL11172880 T PL 11172880T PL 11172880 T PL11172880 T PL 11172880T PL 2380587 T3 PL2380587 T3 PL 2380587T3
Authority
PL
Poland
Prior art keywords
inhibitor
ischemia
reperfusion injury
prevention
reperfusion
Prior art date
Application number
PL11172880T
Other languages
English (en)
Inventor
Maurice Mannesse
Johannes Henricus Nuijens
Frank Pieper
Simoni Maria Grazia De
Gijsbertus Johannes Ziere
Original Assignee
Pharming Intellectual Property B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharming Intellectual Property B.V. filed Critical Pharming Intellectual Property B.V.
Publication of PL2380587T3 publication Critical patent/PL2380587T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
PL11172880T 2005-12-21 2006-12-19 Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu PL2380587T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05112630 2005-12-21
US76094406P 2006-01-23 2006-01-23
EP06824316A EP1965831B1 (en) 2005-12-21 2006-12-19 Use of c1 inhibitor for the prevention of ischemia-reperfusion injury
EP11172880.4A EP2380587B1 (en) 2005-12-21 2006-12-19 Use of C1 inhibitor for the prevention of ischemia-reperfusion injury

Publications (1)

Publication Number Publication Date
PL2380587T3 true PL2380587T3 (pl) 2018-03-30

Family

ID=38016640

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11172880T PL2380587T3 (pl) 2005-12-21 2006-12-19 Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
PL06824316T PL1965831T3 (pl) 2005-12-21 2006-12-19 Zastosowanie inhibitora C1 do profilaktyki uszkodzenia niedokrwienno-reperfuzyjnego

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL06824316T PL1965831T3 (pl) 2005-12-21 2006-12-19 Zastosowanie inhibitora C1 do profilaktyki uszkodzenia niedokrwienno-reperfuzyjnego

Country Status (15)

Country Link
US (3) US8071532B2 (pl)
EP (2) EP1965831B1 (pl)
JP (2) JP5394748B2 (pl)
KR (1) KR101508668B1 (pl)
AT (1) ATE516043T1 (pl)
AU (1) AU2006327989B2 (pl)
CA (1) CA2632400C (pl)
CY (2) CY1112452T1 (pl)
DK (1) DK2380587T3 (pl)
HR (2) HRP20110622T1 (pl)
IL (2) IL192180A (pl)
NZ (1) NZ568749A (pl)
PL (2) PL2380587T3 (pl)
SI (1) SI2380587T1 (pl)
WO (1) WO2007073186A2 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ539472A (en) * 2002-10-17 2008-05-30 Pharming Intellectual Pty Bv Protein modification
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
DK2698166T3 (en) * 2006-10-10 2015-12-21 Regenesance B V KOMPLEMENTÆRHÆMNING FOR BETTER nerves GENERATION
JP5423266B2 (ja) * 2009-09-14 2014-02-19 富士電機株式会社 デジタル制御スイッチング電源装置
CA2829037C (en) * 2011-03-09 2022-05-17 Csl Behring Gmbh Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
EP2497489A1 (en) * 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
CN104010656B (zh) 2011-09-24 2016-02-24 德国杰特贝林生物制品有限公司 使用免疫球蛋白和c1-抑制剂的联合疗法
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN104080474B (zh) * 2011-12-22 2016-04-27 德国杰特贝林生物制品有限公司 C1-抑制剂在治疗中枢神经系统继发性水肿中的应用
WO2014008242A1 (en) * 2012-07-03 2014-01-09 The Trustees Of Columbia University In The City Of New York The use of interleukin-11 to protect against ischemia and reperfusion injury
JP6538561B2 (ja) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
WO2014071206A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
US10441631B2 (en) 2013-02-28 2019-10-15 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
WO2014135694A1 (en) 2013-03-08 2014-09-12 Csl Behring Ag Treatment and prevention of remote ischemia-reperfusion injury
MX389449B (es) 2013-03-15 2025-03-20 Viropharma Biologics Llc Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
WO2014207199A1 (en) 2013-06-28 2014-12-31 Csl Behring Gmbh Combination therapy using a factor xii inhibitor and a c1-inhibitor
DK3215221T3 (da) * 2014-11-03 2020-05-11 Thrombolytic Science Llc Fremgangsmåder og sammensætninger til sikker og effektiv trombolyse
SI3280440T1 (sl) 2015-04-06 2023-03-31 Bioverativ Usa Inc. Humanizirana protitelesa proti C1S in načini uporabe
WO2016196070A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
US12209116B2 (en) * 2015-11-19 2025-01-28 Takeda Pharmaceutical Company Limited Recombinant human C1 esterase inhibitor and uses thereof
EP3493832A1 (en) 2016-08-05 2019-06-12 CSL Behring GmbH Pharmaceutical formulations of c1 esterase inhibitor
US20190183991A1 (en) 2016-08-23 2019-06-20 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
KR102891406B1 (ko) 2016-10-12 2025-11-27 바이오버라티브 유에스에이 인코포레이티드 항-C1s 항체 및 그의 사용 방법
WO2018232305A1 (en) 2017-06-16 2018-12-20 Thrombolytic Science, Llc Methods and compositions for thrombolysis
EP3681517B1 (en) 2017-09-15 2024-05-08 Cedars-Sinai Medical Center C1 esterase inhibitors for use in improving organ function in organ transplant patients
ES2982000T3 (es) 2018-02-28 2024-10-14 Pharming Intellectual Property B V Tratamiento y prevención de la preeclampsia
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
BR112021005228A2 (pt) 2018-10-17 2021-06-15 Csl Behring Gmbh processo para purificar c1-inh
JP2022538355A (ja) 2019-07-04 2022-09-01 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Ｃ１－ｉｎｈを精製する方法
KR102191500B1 (ko) 2020-03-30 2020-12-15 국립낙동강생물자원관 초석잠 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
EP3895726A1 (en) * 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
KR102217607B1 (ko) 2020-06-01 2021-02-18 국립낙동강생물자원관 석창포 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
KR102191452B1 (ko) 2020-06-30 2020-12-15 주식회사 에이치비헬스케어 곶감 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
KR20230110563A (ko) 2020-11-20 2023-07-24 체에스엘 베링 게엠베하 항체 매개 거부 반응의 치료 방법
CA3225079A1 (en) 2021-07-09 2023-01-12 Bruno Giannetti Using c1 esterase inhibitor to treat viral infection-related symptoms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781135B2 (en) 1999-05-14 2005-05-05 Thomas Vorup Jensen Recombinant human mannan-binding lectin
DK1252184T3 (da) * 2000-01-31 2008-02-04 Pharming Intellectual Pty Bv Human C1-inhibitor produceret i mælk af transgene dyr
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
JP2004100982A (ja) * 2002-09-05 2004-04-02 Denso Corp 熱交換器
NZ539472A (en) 2002-10-17 2008-05-30 Pharming Intellectual Pty Bv Protein modification
PL1626736T3 (pl) * 2003-05-16 2021-05-04 Pharming Intellectual Property B.V. Inhibitor c1 o krótkim okresie półtrwania do leczenia przejściowego
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu

Also Published As

Publication number Publication date
WO2007073186A3 (en) 2007-08-09
JP5394748B2 (ja) 2014-01-22
JP2013126992A (ja) 2013-06-27
NZ568749A (en) 2011-05-27
AU2006327989B2 (en) 2012-06-07
IL228954A0 (en) 2013-12-31
ATE516043T1 (de) 2011-07-15
IL228954A (en) 2016-10-31
DK2380587T3 (en) 2017-12-04
US20120088728A1 (en) 2012-04-12
CA2632400A1 (en) 2007-06-28
WO2007073186A2 (en) 2007-06-28
IL192180A0 (en) 2009-02-11
US8415288B2 (en) 2013-04-09
CY1119818T1 (el) 2018-06-27
EP2380587B1 (en) 2017-10-25
US9211318B2 (en) 2015-12-15
EP2380587A1 (en) 2011-10-26
EP1965831A2 (en) 2008-09-10
HRP20110622T1 (hr) 2011-09-30
CA2632400C (en) 2016-06-07
JP2009520815A (ja) 2009-05-28
US20130244941A1 (en) 2013-09-19
US20080305993A1 (en) 2008-12-11
AU2006327989A1 (en) 2007-06-28
EP1965831B1 (en) 2011-07-13
PL1965831T3 (pl) 2011-12-30
HRP20171738T1 (hr) 2018-01-26
KR101508668B1 (ko) 2015-04-06
IL192180A (en) 2013-10-31
US8071532B2 (en) 2011-12-06
SI2380587T1 (en) 2018-03-30
KR20080098001A (ko) 2008-11-06
CY1112452T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
IL228954A0 (en) Use of C1 inhibitors for the prevention of ischemia-reperfusion injuries
MX2007007409A (es) Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos.
MX2009008338A (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
UA101943C2 (ru) Биарилзамещенные гетероциклические ингибиторы lta4h для лечения воспаления
IL191629A0 (en) Tricyclic amide derivatives useful for treating obesity
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
JO2372B1 (en) Source drugs of 4-phenylpyridine derivatives
GB0225475D0 (en) Therapeutic agents
UA92355C2 (en) urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS
WO2003002530A3 (en) Pyrrolidines as dipeptidyl peptidase inhibitors
ZA200704910B (en) Pyrrolidine inhibitors of IAP
WO2008151288A3 (en) Aromatic and heteroaromatic compounds useful in treating iron disorders
IL193252A0 (en) N-hydroxyacrylamide compounds
MX2009010083A (es) Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro.
UA87843C2 (ru) Применение пептидных соединений для лечения расстройств функционирования мотонейронов или/и периферических невропатий
PL1855677T3 (pl) 3,11B-Cis-dihydrotetrabenazyny do leczenia schizofrenii i innych psychoz
MX2007009070A (es) (spm 927) para terapia supletoria de esquizofrenia.
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
MY145823A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
EP2036555A4 (en) USE OF PYRIDONE DERIVATIVES FOR THE PREVENTION AND TREATMENT OF RADIOACTIVE LUNG INJURY
WO2008036316A3 (en) Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2009148600A8 (en) Deuterated lysine-based compounds
TW200738643A (en) Cyclourea compounds and the use thereof
WO2006050861A3 (en) Statine derivatives for the treatment of alzheimer's disease
TW200637538A (en) Lacosamide for add-on-therapy